This proposal is concerned with two characteristics that we have found most relevant to transformation: 1) activation consequences of erbB signaling complexes and 2) the physical interactions and linkage of the erbB transforming machinery to certain protein elements of the centrosome that guide mitosis and cytokinesis. These studies are an extension of previously funded efforts to understand the erbB receptor assembly and specific signaling events that emanate from an active or inactive receptor complex. We have found that a malignant tumor cell could be rendered more normal by disabling the erbB receptor complex with monoclonal antibodies or mimetics. Reversal of phenotype occurred in malignant cells with multiple abnormal centrosomes. Moreover, we have now found that activated p185-EGFR heteromeric receptor complexes lead to elevated levels of Survivin, a protein associated with the centrosome. We were successful in cloning a novel gene, Su48, which encodes a centrosome-associated protein that physically associates with Survivin. Su48 is highly expressed in a number of tumor cell lines. Ectopic expression of Su48 and its mutant forms can cause abnormal mitosis and abnormal DNA content which correlates with aneuploidy (Rapi, et al. 1996). We hypothesize that disruption of normal Su48 functions causes centrosome dysfunction and abnormal spindle formation. This process contributes to aberrant distribution of chromosomes and progressive malignant transformation. We have found that Su48 associates with specific kinases and proteins that are relevant to mitosis and accumulation of genetic abnormalities. In the proposed studies we will examine features of receptor complex formation that are essential as a transforming mechanism in breast tumors. Next, we will define the molecular functions of Su48 during centrosome duplication, spindle formation, and cytokinesis. In addition, we will investigate the role of Su48 in malignant transformation. Collectively, the studies will analyze certain properties of the signaling complex and associated novel proteins that are part of the centrosome. These studies will improve our understanding of the roles of Su48 in mitosis and cancer development. Characterization of Su48 and its related signaling molecules may provide novel markers for early detection and diagnosis of breast cancers as well as new targets for therapy. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA089481-05
Application #
6876508
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Spalholz, Barbara A
Project Start
2001-02-01
Project End
2009-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
5
Fiscal Year
2005
Total Cost
$263,506
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Kanzaki, Hirotaka; Mukhopadhya, Nishit K; Cui, Xiaojiang et al. (2016) Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-?B-Activation. Monoclon Antib Immunodiagn Immunother 35:1-11
Nagai, Yasuhiro; Tsuchiya, Hiromichi; Runkle, E Aaron et al. (2015) Disabling of the erbB Pathway Followed by IFN-? Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors. Cell Rep 12:2049-59
Morvaridi, Susan; Dhall, Deepti; Greene, Mark I et al. (2015) Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. Sci Rep 5:16759
Ruan, Hang; Hao, Susan; Young, Peter et al. (2015) Targeting Cathepsin B for Cancer Therapies. Horiz Cancer Res 56:23-40
Lam, Lian; Czerniecki, Brian J; Fitzpatrick, Elizabeth et al. (2014) Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer. J Mol Biomark Diagn 4:151
Zhang, Hongtao (2013) Empowering scFv with effector cell functions for improved anticancer therapeutics. Oncoimmunology 2:e24439
Cai, Zheng; Fu, Ting; Nagai, Yasuhiro et al. (2013) scFv-based ""Grababody"" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors. Cancer Res 73:2619-27
Du, Taofeng; Nagai, Yasuhiro; Xiao, Yan et al. (2013) Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers. Exp Mol Pathol 95:38-45
Huang, J-M; Nagatomo, I; Suzuki, E et al. (2013) YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene 32:2220-9
Murali, Ramachandran; Greene, Mark I (2012) Structure based antibody-like peptidomimetics. Pharmaceuticals (Basel) 5:209-35

Showing the most recent 10 out of 16 publications